PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed:

• Opportunities and challenges in conducting virtual bioequivalence
• IVIVE-PBPK in biopharmaceutics
• An quantitative risk assessment approach for virtual bioequivalence
• Role of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence